Mechanistically, targeting CD47 effectively remodeled the tumor immune microenvironment, promoting the transition of macrophages from an immunosuppressive, anti-inflammatory state toward a pro-inflammatory, anti-tumor phenotype, while simultaneously enhancing the activation and infiltration of CD8+ T cells [13]. The gene discussed is CD47; the disease is neoplasm.